type of report	Current report
number	27/2013
company	PHARMENA

## **Publication of prospectus**

The Management Board of PHARMENA S.A. informs that on 22<sup>nd</sup> May 2013, the Issuer's prospectus was published on the Issuer's website (www.pharmena.com.pl) and on its Lead Manager's website, i.e. brokerage house Dom Maklerski Prospectus S.A. (www.dmprospectus.pl). The prospectus was drawn up in connection with the planned public offering of up to 1,759,010 (one million seven hundred fifty-nine thousand and ten) series D ordinary bearer shares with preemptive rights.

The goal of the issue of series D shares is to obtain funds for clinical trials of innovative anti-atherosclerosis medicinal product 1-MNA in the scope of phase II ("Proof of Concept").

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

## Representatives of the company:

- Konrad Palka President of the Board
- Marzena Wieczorkowska Vice President of the Board